P-BIO™

Portugal's Biotech Cluster

Discovery is in our DNA

www.pbioportugal.pt

CONTENTS

P-BIO™

Portugal's Biotech Cluster

P-BIO – Discovery is in our DNA

After three decades of strong investment in basic science and a recent burst in seed and start-up capital, Portugal is becoming a hub for biotech entrepreneurs searching for a place where quality of life meets high business standards and cutting-edge research. Leveraging on a young and internationally trained population of PhDs, engineers and business graduates, Portugal's life science industry gravitates around the regions of Lisbon, Europe's most vibrant capital, Coimbra, a modern "city-of-knowledge" with a 725-year old university, and Porto, where some of the best cancer research in the world is produced. While Portugal´s healthcare sector has been growing steadily, with exports surpassing those of traditional industries such as wine or cork, the country has become a leading example of innovation in fields such as renewable energy, agro-food and textiles. Biotechnology is being used by companies large and small to further advance these industries.

With a centuries-old tradition as a bridge between civilizations, a stable social and political system, and a forward-looking mentality, Portugal is the perfect hub for scientific and business cooperation between Europe and the World.



PROMOTERS

DESCRIPTION

BIOCANT is a CLUSTER of companies and R&D institutions of excellence with a strong commitment to science education and entrepreneurship.

A unique ecosystem that covers the entire INNOVATION PIPELINE, from the knowledge generation and human resources training to the market, including tech transfer, financing, scientific dissemination and industrial production.

It gathers 30% of the total national number of BIOTECH COMPANIES and provides a wide variety of services and opportunities to develop a competitive business.

SCIENCE AND
TECHNOLOGY PARK

BIOTECHNOLOGY

INNOVATION AND
ENTREPRENEURSHIP SUPPORT

Biocant is the first Portuguese Science and Technology Park specialized on Biotechnology where advanced life sciences knowledge and technology are developed and applied creating value in business initiatives.

Biocant offers state of the art and high throughput technologies and world-class trained human resources prepared to do applied R&D in the field of Biotechnology. The model is translated into a series of activities that fosters economic development through IP licensing, company creation or joint venture initiatives.

SERVICES

The Park offers a wide variety of opportunities to develop your business:
/ Facilitate Access to Capital
/ IP Management
/ Tailor-made Research Services
/ Customized Labs and Office Areas
/ Economic and Scientific Validation of Early-stage Projects
/ Shared facilities (technological platforms and industrial pilot unit)
/ Virtual Incubation Services
/ Access to National and International Networks
/ Land Properties for Companies and R&D Centers

FACILITIES

/ R&D CENTER: Applied R&D center with sophisticated equipment, clean rooms and well-trained researchers and technicians.
/ MAIN BUILDING: facilities to a variety of needs such as congresses, seminars, workshops, training, commercial/business presentations or other events.
/ BIOPILOT UNIT: industrial pilot scale unit for the production of small batches of products testing industrial biotechnology processes at pilot scale for technological and economic validation.
/ BIOCANT SME's: customized / scalable laboratories available for companies' incubation.
/ UC BIOTECH: applied R&D center for biotechnology and advanced training in business environment from the Center for Neuroscience and Cell Biology (CNC) - the first associated laboratory in the country and the largest research center in the Region with over 400 members.
/ BIOCANT SME´s II: customized / scalable laboratories available for companies' incubation.

THE COMPANIES

The companies at Biocant are small and medium sized focused on innovation and knowledge, with particular emphasis on the generation of valuable Intellectual Property. The current companies are in various stages of development and are of different sizes, from business services and products with regular sales to companies whose business model is focused exclusively on the value of their R&D activity. In common they share a high degree of internationalization of their activities and skilled human resources.

CONTACTS:

Contact Name: Carlos Faro

Address:
Biocant – Technology Transfer Association
Biocant Park, Núcleo 04, Lote 02
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 890
Fax: (+351) 231 410 899
Email: info@biocant.pt
www.biocant.pt

P-BIO

Portugal's Biotechnology Industry Organization

Associação Portuguesa de BioIndústria

DESCRIPTION

Portugal's Biotechnology Industry Organization (P-BIO) is the sole association of life science companies in Portugal, representing the vast majority of the country's biotechnology corporations. P-BIO was created in 1999 (as APBio), and since then has been a key player in the support and promotion of Portuguese biotechnology. P-BIO acts by fostering a favorable environment for start-up creation and growth, promoting national and international business, and increasing public awareness of biotechnology products and breakthroughs. A member of EuropaBio, the association is the key link between Portuguese biotech companies and relevant players such as the government, investors, regulatory agencies and the more established industries.



BIOTECHNOLOGY

POLICY

ASSOCIATION

Portugal's Biotechnology Industry Organization (P-BIO) represents the vast majority of the country's Life Science companies. Our aim is to enable the success and global competitiveness of the industry by creating a favorable environment for its development and growth into a dynamic global cluster. Portugal is the Atlantic coast of Europe and P-BIO can be the bridge between your company and the rest of the World.

MEMBERS

Alexion Services Europe
www.alexionpharma.com
AMGEN Biofarmacêutica, Lda.
www.amgen.com
Biocant, Centro de Inovação em Biotecnologia
www.biocant.com
Bioingenium Unipessoal, Lda.
www.bioingenium.pt
BioMarin Europe Ltd
www.bmrn.com
Biopremier - Inovação e Serviços em Biotecnologia, Lda.
www.biopremier.com
Biotrend - Inovação e Engenharia em Biotecnologia S.A.
www.biotrend.biz
Celgene Portugal
www.celgene.eu/portugal.aspx
Cell2B- Terapias para a Saúde
www.cell2b.com
CBRA Genomics, Lda.
www.coimbragenomics.com
ECBio - Investigação e Desenvolvimento em Biotecnologia, S.A.
www.ecbio.com
Equigerminal, S.A.
www.equigerminal.org
Eurotrials - Consultores Científicos, S.A.
www.eurotrials.com
Gene PreDiT
www.genepredit.com.pt
Genlbet Biopharmaceuticals
www.genibet.com
Genzyme- a Sanofi Company Sanofi- Produtos Farmacêuticos, Lda.
www.genzyme.com.pt
Hitag Biotechnology, Lda.
www.hitag.pt
Klon, Innovative Technologies from Cloning S.A.
www.klon.pt
Lymphact - Lymphocyte Activation Technologies, S.A.
www.lymphact.com
Luzitin, S.A.
www.luzitin.pt
MadeBiotech, S.A.
www.madebiotech.com
Monsanto II, Produtos Químicos e Agrícolas, Sociedade Unipessoal, Lda.
www.monsanto.com
Pfizer
www.pfizer.pt
Sartorius SA Representação em Portugal
www.sartorius.com
Shire, S.A.
www.shire.com
Silicolife, Lda.
www.silicolife.com
Sobi- Swedish Orphan Biovitrium, S.L
www.sobi.com
Sociedade Portuguesa de Inovação- C.E.F.I. SA
www.spi.pt
Spinlogic
www.porto.ucp.pt\spinlogic
Stemmatters, Biotecnologia e Medicina Regenerativa, S.A.
www.stemmatters.com
Synageva BioPharma Corp.
www.synageva.com
Technophage, S.A.
www.technophage.pt
Thelial Technologies
www.thelial.com

CONTACTS:

Contact Name: Sara Monteiro

Address:
P-BIO - Portugal's Biotechnology Industry Organization
Biocant Park, Núcleo 04, Lote 02,
3060-197 Cantanhede, PORTUGAL

Phone: (+ 351) 231 410 960
Fax: (+ 351) 231 410 961
Email: smonteiro@p-bio.org
www.p-bio.org



COMPANIES

biotrend
Inovação e engenharia em biotecnologia

DELIVERING SUSTAINABLE VALUE

DESCRIPTION

Biotrend is a research-based company focused on the development, optimization, de-risking, integration and scale-up of bioprocesses for the production of bio-based chemicals, materials and fuels from renewable raw materials, including complex industrial by-products and wastes. We offer contract research and development services and develop new technologies to be licensed out to industrial clients. We actively participate in international collaborative projects encompassing the full bioeconomy value chain, keeping Biotrend at the forefront of scientific development.

BIOENGINEERING

INDUSTRIAL BIOTECHNOLOGY

PROCESS DEVELOPMENT

From renewable resources and wastes to value-added products, Biotrend develops bioprocesses for a sustainable and profitable industry.

PRODUCTS & SERVICES

/ *Microbial strain screening:* Platform to screen biocatalysts and process conditions. Typical screening includes strains producing a specific compound or able to cope with specific medium requirements (ex. use C5 carbon sources or tolerate inhibitors).

/ *Process development and optimization:* Strategies for maximizing productivity, yield and titer, seeking integration opportunities with raw material pretreatment and downstream processing.

/ *Process scale-up, de-risking and validation:* 2, 10, 50 and 250L fermenters for thorough scale-up studies and process de-risking. Access to facilities of 1,000-100,000L capacity.

Experience in diverse microbial systems, from marine bacteria to engineered yeasts, processing a variety of raw materials for the production of biopolymers, intermediate and base chemicals. We design processes to meet economical and sustainability requirements and outperform conventional petro-based processes, while ensuring scalability, reproducibility and robustness.

TARGET MARKETS / CLIENTS

Clients range from start-up companies without bioprocessing know-how or infrastructure to large companies exploring opportunities of biotechnology and of the use of renewable raw materials, including by-products and wastes. Current examples:

/ *Large pulp and paper company:* Fermentation-based valorization of carbon-rich waste streams from pulp and paper mills.

/ *Leading confectionery multinational and leading plastics research institute:* Transformation of carbohydrate-rich solid residues into materials suitable for packaging applications.

/ *Innovative enzyme engineering company:* Increase the productivity and reduce the enzyme production cost.

/ *Marine biotech start-up:* Increase the yield and productivity of the production of cell extracts with cosmetic use.

/ *Beverage company:* Increase the robustness and scale-up of the production of an innovative fermented beverage.

Proprietary technologies are also available to be out-licensed. Contact for further information or refer to our website.

CONTACTS:

Contact Name: Bruno Sommer Ferreira

Address:
Biotrend - Inovação e Engenharia em Biotecnologia S.A.
Biocant Park, Núcleo 04, Lote 2,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 940
Email: bsf@biotrend.biz
www.biotrend.biz

bluepharma®
Indústria Farmacêutica, S.A.

A PARTNER THAT CARES

DESCRIPTION

Bluepharma offers an **integrated approach** on the process of drug discovery and development, including **innovative research** on new chemical and therapeutic entities (based on **novel drug delivery platforms**) as well as formulation development, clinical **research**, **manufacturing** and **commercialization** of medicines.

The various various start-up companies affiliated to Bluepharma offer:

BSIM2 – Lead discovery & optimization through computational methodologies and workflows
LUZITIN – NCE for photodynamic therapy
TREAT-U- Targeted nanotechnology-based platforms for cancer
BLUECLINICAL- Clinical Research activities (from phase I-IV)



PHARMACEUTICAL DEVELOPMENT

CLINICS

MANUFACTURING

Bluepharma operates at all stages of the drug development process, from lead compound identification and optimization, formulation development, clinical research, scale-up and manufacturing of the final product.

PRODUCTS & SERVICES

1. R&D

1.1) Dedicated facilities focused on the development of solid dosage forms, including pre- and formulation studies, development of analytical methods, scale up, ICH stability and compilation of CMC.
1.2) Novel and versatile oral strip formulations providing solutions for unmet medical needs.
1.3) Innovative photosensitizer compounds used in Photodynamic Therapy or Photodiagnosis of cancer or other diseases; One of the lead compounds (LUZ11) is currently at phase IIa clinical trials in advanced head and neck cancer.
1.4) Clinical pharmacology unit devoted to phase 1 clinical trials.

2. Industrial activities

2.1) State-of-the-art manufacturing site for solid dosage forms; approved by USFDA, KFDA and EU authorities; capacity for 2.0 b. units (tablets and capsules).

3. Commercialization of medicines

3.1) Large portfolio of products covering the main therapeutic areas; export activities worldwide.

TARGET MARKETS / CLIENTS

Bluepharma's integrated approach widens its scope of potential partners, namely through:

1. Full pharmaceutical development for solid dosage forms, including manufacturing of clinical trial batches, stability studies, regulatory support and first in man studies (facilities approved by EMA and FDA)

As a pharmaceutical company operating worldwide, Bluepharma seeks to license out its technology and establish partnerships for co-development projects or industrial projects.

2. On the other hand, Bluepharma's patented innovative technologies have proved critical when approaching new partners:

/ LUZ11, a photosensitizer specifically designed for the treatment of cancer, improving efficacy/safety/convenience over the existing market competitors, mainly seeks to establish partnerships with either pharmaceutical companies operating in the oncology field and / or health investment funds that have a vested interest in oncology.

/ Novel and versatile oral strip formulations, providing solutions for unmet medical needs.

CONTACTS:

Contact Name: Sérgio Simões

Address:
Bluepharma
S. Martinho do Bispo,
3045-016 Coimbra, PORTUGAL

Phone: (+351) 239 800 300
Fax: (+351) 239 800 333
Email: ssimoes@bluepharma.pt
www.bluepharma.pt

BSIM²

COMPUTER-DRIVEN DRUG DISCOVERY

DESCRIPTION

BSIM² is at the forefront of computing technologies to discover the drugs of the future.

Streamlining drug discovery through:
- / Cheminformatics,
- / Structural Bioinformatics,
- / Network and Systems Pharmacology,

and cutting-edge hardware.

Integrating all discovery stages with Academia and CROs, for:
- / Chemical synthesis,
- / *In vitro* and *in vivo* proof-of-concept,
- / Pharmaceutical development.

Making drug candidates against neurodegenerative diseases, steered for:
- / High efficacy,
- / Higher safety,
- / Optimal properties for long-term therapies.



DRUG
DISCOVERY

SMALL MOLECULE
THERAPEUTICS

NEURODEGENERATIVE
DISEASES

We craft small-molecule therapeutics for neurodegenerative diseases by harnessing the power of distributed knowledge, the tools of discovery informatics, and a holistic approach to drug discovery.

PRODUCTS & SERVICES

BSIM² is building a portfolio of drug candidates against fatal or impairing neurodegenerative diseases. The fist product in the pipeline is directed to a rare, fatal peripheral neuropathy — Familial Amyloid Polyneuropathy (FAP). The discovery and optimization of lead compounds holding pharmacological properties unmatched by any known inhibitor of transthyretin-related amyloid offers promise for safe treatments of FAP, FAC (Familial Amyloid Cardiomyopathy), and other transthyretin-related amyloidoses.

Compared with the only solution in the market, our candidates display critical advantages:

/ Strongest in vitro inhibitory activity against amyloid formation;

/ Lowest cytotoxicity in cell viability assays;

/ Optimal physicochemical properties for long-term therapies.

TARGET MARKETS / CLIENTS

Increased longevity and quality of life are ancient longings of human societies, but never like today were they so pressing. Human ageing and age-related diseases show increasing trends and represent today one of the biggest challenges facing Society and the pharmaceutical industry. BSIM² potential customers are Pharma and Biotech companies willing to replenish their portfolios with novel therapies against:

/ Rare, fatal or impairing amyloidoses like Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) — affecting ca. 50,000 patients worldwide;

/ Age-related diseases like Senile Systemic Amyloidosis, Parkinson's disease and Alzheimer's disease — altogether affecting more than 30 million people worldwide.

BSIM² is currently seeking a joint-venture agreement to continue product development, or alternatively an IP licensing agreement of the company's first products to fight FAP. BSIM² is the sole owner of the commercial rights of the IP relating to the compounds in development for the treatment of transthyretin-related amyloidoses.

The target market of FAP alone has been estimated in excess of 1 billion US dollars.

CONTACTS:

Contact Name: Rui M. Brito

Address:
BSIM²
Biocant Park, Núcleo 04, Lote 02,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 892
Fax: (+351) 231 410 901
Email: info@bsimsquare.com
www.bsimsquare.com

DESCRIPTION

At Cell2B we focus in treating unmet immune and inflammatory diseases with our mesenchymal stem cell technology - ImmuneSafe®. We have the European Medicine Agency's clearance to start clinical trials for the treatment of steroid-refractory acute and severe Graft-versus-Host-Disease (GvHD). Orphan designation has been granted in Europe. An early clinical study of the technology showed that it was safe in six patients suffering from GvHD.

REGENERATIVE MEDICINE

CELL-BASED THERAPIES

For patients with immunological or inflammatory unmet clinical needs.

PRODUCTS & SERVICES

ImmuneSafe® is composed of mesenchymal cells (MSC) expanded ex-vivo in xeno-free media. We isolate our MSC from the mononuclear cell fraction of the bone marrow of healthy donors using an automated system. These cells are then seeded in a Cell2B's proprietary extracellular matrix platform, in xeno-free media. The result is a unique cell product with a distinct potency profile.

TARGET MARKETS / CLIENTS

The current cost of treatment for immune and inflammatory responses exceeds €80 Billion per year worldwide. More than half of this amount is associated with medical procedures, chronic immunosuppressive or anti-inflammatory therapy, and hospitalization due to complications resulting from the chronic use of these drugs. The market for immunosuppressants – the current standard of care – in Europe is estimated to grow from €2 Billion in 2012 to €2.8 B in 2017 at a compound annual growth rate of 6.1%.

CONTACTS:

Contact Name: Daniela Couto

Address:
Cell2B - Advanced Therapeutics S.A.
Biocant Park, Núcleo 04, Lote 4A,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 906
Email: cell2b@cell2b.com
www.cell2b.com

DESCRIPTION

Coimbra Genomics develops tools that give medical doctors easy access to the ever growing wealth of genomic information and help them apply it for the benefit of their patients, in useful time and in a practical manner. Aiming to stay at the forefront of genomic knowledge, Coimbra Genomics also leads innovative R&D projects in search for biomarkers for important unmet medical needs.

Coimbra Genomics was launched by Critical Software, the Biocant Park and a group of experienced entrepreneurs and scientists. The company was funded by two VC firms and is partnering with a growing network of physicians, from several specialties, in leading healthcare units.



PERSONALIZED MEDICINE

GENOMICS

CLINICAL SOFTWARE

Coimbra Genomics develops tools that bring genomic knowledge to the desktop of every physician, making personalized medicine a reality.
Because health is a personal matter.

PRODUCTS & SERVICES

Coimbra Genomics develops software tools for precision medicine. Our technology allows any Medical Doctor, anywhere, to consult their patients' genome or exome sequence through standardized queries, and quickly obtain easy-to-read reports with validated information relevant for the clinical decisions at stake. We provide **a simple, scalable and secure way to perform personalized medicine**.

Coimbra Genomics' technology can be used by any physician, regardless of previous knowledge in genetics, without stopping patient flow or requiring learning on the spot. Its extreme flexibility allows coupling to any sequencing technology (Illumina, LifeTech, Complete Genomics, etc) and compliance with different legal and logistic requirements. One of the system's several additional features permits the accumulation of clinical data and its matching to genetic information to unveil valuable genome-phenome correlations.

Aiming to stay at the forefront of genomic knowledge, Coimbra Genomics also leads innovative R&D projects in search for biomarkers of diseases representing important unmet medical needs. The first such project focuses on **gastric cancer** and has begun in late 2013 with the genomic, transcriptomic and methylomic characterization of 100 well-characterized samples in collaboration with BGI and expert cancer center IPATIMUP.

TARGET MARKETS / CLIENTS

Medical doctors of all specialties; healthcare centers.

Europe, North America, Latin America, Asia.

CONTACTS:

Contact Name: Nuno Arantes-Oliveira

Address:
Coimbra Genomics, S.A.
Biocant Park, Núcleo 04, Lote 02,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 890
Email: info@coimbra-genomics.com
www.coimbra-genomics.com

crioestaminal
Ciência para a vida

DESCRIPTION

Crioestaminal is a Portuguese stem cell therapeutics company founded in 2003. Its activity is based on two pillars – cryopreservation of stem cells and the development of advanced cell therapy products. Crioestaminal was the first stem cell bank to operate in the Iberian Peninsula and is today a top 5 player in Europe. It is the only Iberian stem cell bank with an accreditation by AABB, which serves as proof of its high quality standards and enables it to conduct FDA-approved trials. It has invested significantly in R&D and established partnerships with top scientific institutions in Portugal.

STEM CELLS

For parents that want to cryopreserve their children's stem cells, Crioestaminal is the familiy bank that offers most security because of its experience, its rigor and its technology.

PRODUCTS & SERVICES

/ Crioestaminal offers cryopreservation services for cord blood and tissue stem cells. It was the first company to offer 4 different methods to process cord blood and tissue. Furthermore, Crioestaminal stores the samples for 25 years. Its experience of having served more than 60.000 clients, its commitment to highest quality standards and ability to innovate are the foundation of its market leadership position in multiple markets.

/ Crioestaminal's investments in R&D to develop new cell therapy products have resulted in two international patents. First, a therapeutic formulation that is a gel with a co-culture of stem cells from umbilical cord blood and endothelial cells. The technology has shown the potential to accelerate the healing of chronic wounds by 2,5 times, that could be useful in particular in diabetic patients. In 2013, it registered a second patent, a formulation containing cord blood stem cells and lysophosphatidic acid that is used for cardiac regeneration after myocardial infarcts.

TARGET MARKETS / CLIENTS

/ For its cryopreservation services, Crioestaminal's final customer are parents to be. The company is interested in entering new geographies, either alone or through joint ventures with local investors or healthcare related partners.

/ Regarding its cell therapy products that will be used in hospital settings, Crioestaminal is open to explore different options of taking the products to market (e.g., licensing).

CONTACTS:

Contact Name: André Gomes

Address:
Crioestaminal - Saúde e Tecnologia, S.A.
Biocant Park, Núcleo 4, Lote 2,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 305 060
Fax: (+351) 231 267 326
Email: info@crioestaminal.pt
www.crioestaminal.pt

DESCRIPTION

Equigerminal is a VC backed private company fully dedicated to field of biotechnology applied to horses, that aims to become a world class Equine Biotech player.

The company is focused on a high value market segment - the high health and performance horses, developing proprietary intellectual property on horse infectious diseases and genetics for diagnostics and therapeutics purposes, with the goal to empower horse's health and genetics.

As a result of years of research, Equigerminal successfully identified a New Equine Virus (NEV) that is highly cytophatic in equine fibroblastic and macrophage cell lines. The company has already developed and patented a competitive ELISA diagnostic test, having also patented an antiviral drug.

IN VITRO DIAGNOSTICS
FOR EQUINES

Developing proprietary, innovative technology in diagnostics & therapeutics for equines. Emergent diseases. More than 75% of emergent viruses are of animal origin.

PRODUCTS & SERVICES

For the past 4 years, Equigerminal was able to translate R&D knowledge on equine virology into the identification, characterization and patent protection of: (i) a New Equine Virus; (ii) a diagnostic kit for the new virus; (iii) a possible therapeutic agent against the new virus.

/ NEV identification, description and propagation (Patent submitted)
/ Diagnostic ELISA Kit (Patent submitted)
/ Antiviral Drug (Patent submitted)

The company also provides laboratory services (under an ISO 17025 environment, application submitted) to veterinarians, horse owners, breeders and sports/race associations.

Equigerminal currently has two commercial brands:
/ Equihealth - in house services for 30 lab routine diagnostic tests to detect horse pathogens and infections by immunodiagnostics, RT qPCR and RFLP techniques;
/ Equigene - in house services for 20 genetics tests for horse coat color, horse disease and horse performance.

TARGET MARKETS / CLIENTS

To pursue the journey in creating value, Equigerminal is now focusing on 3 main strategic goals in order to bridge the gap from the proprietary disruptive IP to market products. To accomplish this journey, Equigerminal is looking for reference partners (investors or industry wise players) that will help out the company in achieving the following workstreams:

/ NEV Diagnostic Kit commercialization
/ NEV Therapeutic Co-development
/ NEV Clinical Relevance and Therapeutic efficacy

During these initial years, Equigerminal has been focused on delivering all the goals set for the R&D stages, and is now ready to collaborate at these different levels, aiming at taking the potential of the company to the next level together with reference partners.

CONTACTS:

Contact Name: Isabel Fidalgo Carvalho

Address:
Equigerminal, S.A.
Biocant Park, Núcleo 04, Lote 4A,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 965
Email: geral@equigerminal.pt
www.equigerminal.org

FairJourney Biologics

ANTIBODY TAILORING FOR SUCCESS

DESCRIPTION

Fairjourney Biologics is a fast and high quality solutions provider for Monoclonal antibodies needs.

It delivers a range of solutions from antibody discovery to antibody engineering and to antibody variable domain sequencing by combining cutting edge technologies and a highly experienced team.

The Fairjourney royalty-free projects are the result of an efficient process of joint and personal collaboration with the client. Consequently, customized antibodies with very specific characteristics are delivered to you to accomplish success.

ANTIBODY

PHAGE

DISPLAY

Fairjourney Biologics is a fast and high quality solutions provider for Monoclonal antibodies needs.

PRODUCTS & SERVICES

The phage display team with more than 30 years of combined experience and 11 patents on the field successfully delivered in 100% of the cases, therapeutic, diagnostic and other tool antibodies with very specific characteristics, in record time. Our proprietary rodent, human and llama primers together with our experience in DNA and cell immunizations enable us to tackle challenging targets like GPCRs and ion channels.

TARGET MARKETS / CLIENTS

Biopharmaceutical and biotech companies.

CONTACTS:

Contact Name: António Parada

Address:
Fairjourney biologics
Rua do Campo Alegre, EDFC6 1021
4169-007 Porto, PORTUGAL

Phone: (+351) 960 096 632
Email: info@fjb.pt
www.fjb.pt

Gene PreDiT

PREvention, DIagnosis and Treatment

DESCRIPTION

Gene PreDiT is a biotech company dedicated to the development of new therapeutic strategy for obesity. Exploring the potential of our research platforms and the potential of a drug reprofiling approach, we identified a new genetic biomarker for morbid obesity (particularly relevant for male obesity) and also a compound that modulates lipid accumulation. For this compound, we are starting a Proof of Concept Clinical Trial (Phase IIa) to validate both our newly discovered biomarker and the potential of our targeted therapy for obesity.

OBESITY

BIOMARKERS

DRUG DISCOVERY
& DEVELOPMENT

Gene PreDiT is devoted to the development of a new targeted therapy for obesity. Our leading compound will enter Clinical Trials in 2015 to confirm its efficacy and validate our genetic biomarker.

PRODUCTS & SERVICES

Over the past years Gene PreDiT has been focused on obesity, a serious condition that is also a major risk factor for a number of chronic diseases, and we identified a panel of genes relevant for this disease. We have also identified a compound able to modulate lipid accumulation. This new medication will only be directed to patients with the genetic biomarker Gene PreDiT identified, therefore targeting only to the patients that will mostly benefit from the therapy. At the moment Gene PreDiT is dedicated to conduct a Clinical Trial Phase IIa to both validate our new genetic biomarker for obesity and to test the efficacy of our targeted therapy. We also plan to develop a genetic test to identify the patients to whom this therapy should be directed.We are currently looking for partners to either co-develop with us this new medication and conduct the subsequent Clinical Trials needed to reach the market. We are also interested in clients to out-license our results.

TARGET MARKETS / CLIENTS

Our clients are mainly pharmaceutical companies that are focused on the development of new therapies for obesity or the companies that have firstly developed an application with our compound of interest (we have followed a drug repurposing approach). Due to the lack of clearly safe and effective therapies for obesity, this is a field eager for new approaches, and therefore we anticipate a high interest on the product the company is developing. Additionally, the market size and the presence of a genetic test to identify the population to whom this compound is more effective suggests that our product will be well positioned in the value chain. As a future strategy we envision both collaborations to further develop our product (Clinical Trials Phase IIb and/or III) or licensing-out of our results

CONTACTS:

Contact Name: Nuno André Faustino

Address:
Gene PreDiT
Biocant Park - Parque Tecnológico de Cantanhede,
Núcleo 04, Lote 4-A, Edifício Biocant II,
3060-197 Cantanhede - PORTUGAL

Phone: (+351) 231 410 893
Fax: (+351) 231 410 928
Email: andre.faustino@genepredit.com.pt
www.genepredit.com.pt

GenIbet Biopharmaceuticals

A cGMP BRIDGE TO PERSONALIZED MEDICINE

DESCRIPTION

GenIbet is a biopharmaceutical CMO offering highly specialized Microbial, Cell Culture and Viral Process Development and cGMP manufacturing services to research groups, biotech and pharma companies. This, combined with in-house fill and finish capabilities, gives our clients the opportunity to go from bench to clinic in one facility.

GenIbet's core activity is the manufacture and supply of materials for use in early stage drug development, pre-clinical studies and cGMP manufacturing from Phase I to Phase III clinical trials.

BIOPHARMACEUTICAL
CONTRACT MANUFACTURING

GenIbet is a Biopharmaceutical CMO (Contract Manufacturing Organization) specialized in Microbial, Cell Culture and Viral Process Development and ***cGMP Production*** *for Phase I to III clinical trials.*

PRODUCTS & SERVICES

GenIbet has four cGMP Certified units in operation:

/ A Bacterial manufacturing facility (BSL2 Bioreaction room)
/ A unit dedicated to the manufacture of Viral Products for Gene Therapies and Vaccines (BSL2 unit)
/ A unit dedicated to Animal Cell Culture (BSL2 unit)
/ A Fill and Finish Unit offering small scale semi-automatic aseptic filling for clinical trials

In addition, GenIbet has a highy qualified team, high flexibility and a versatile structure allowing the supply of the following services:

/ Biopharmaceutical Process Development
/ cGMP Biopharmaceutical Production (Drug Substance and Drug Product)
/ cGMP Master and Working Cell Bank Production
/ cGMP Master and Working Virus Seed Stock Production
/ cGMP Cell and Gene Therapy Production
/ Fill and Finish
/ Quality Control and Quality Assurance Services
/ Support Dossier to fill with different Regulatory Authorities

TARGET MARKETS / CLIENTS

Biotech/Pharma Companies and Research Groups with biopharmaceutical products or advanced therapies in development, pre-clinical testing or clinical trials.

CONTACTS:

Contact Name: Tiago Ferreira

Address:
GenIbet Biopharmaceuticals
Edifício da Unidade Piloto do iBET, Estação Agronómica Nacional, Avenida da República, 2780-157 Oeiras, PORTUGAL

Phone: (+351) 214 469 484
Fax: (+351) 214 469 480
Email: tiago.ferreira@genibet.com
www.genibet.com

HEARTGENETICS
GENETICS & BIOTECHNOLOGY

KNOWLEDGE THROUGH GENETICS

DESCRIPTION

HeartGenetics was founded in 2013 (IST spin-off) after 7 years of research between multidisciplinary teams including molecular and computational biologists, geneticists and cardiologists from referenced Portuguese Hospitals.

HeartGenetics has developed a disruptive methodology that includes (i) a DNA MICROCHIP array platform and (ii) efficient and scalable algorithms for data processing and clinical reporting.

This new methodology is relevant for improving cardiovascular diagnostics, genetic testing scaling up and providing cost-effective genetic tools to clinical practice.

GENETIC TESTING

BIOINFORMATICS

HeartGenetics develops technologies for cardiovascular genetic testing and clinical reporting. Our products deliver actionable genetic data that medical doctors and health companies use to improve people's health.

PRODUCTS & SERVICES

HeartGenetics' main products are:

A) Cardiovascular Genetic Testing (using DNA Microchip)
HeartGenetics's strategy uses specific knowledge to develop cost-effective genetic tests to specific pathologies, which can improve clinical diagnosis and prognosis and be used by any clinician.

Key benefits

/ test ALL known mutations (as good as sequencing methods)

/ more ACCURATE that sequencing (99% accuracy)

/ much FASTER than sequencing (5 days and not months)

/ cost EFFECTIVE (up to 10 times more)

B) The HeartDecode system
HeartDecode system delivers value through its scalable solutions in data processing and clinical genetic reporting based on sophisticated know-how and computational tools.

Key benefits

/ unique and user-friendly genetic reporting platform

/ enables the efficient generation of an unlimited number of genetic reports. Reports include:
1. Table of results
2. Results interpretation
3. Supporting text and bibliography
4. Language customization

/ independent from genetic testing technology

TARGET MARKETS / CLIENTS

A) HeartGenetics' Genetic Testing
Clinical segments: Cardiology, Obstetrics, Genecology and Ophthalmology.
Clients: Hospitals and clinics; Healthcare channels.

B) HeartDecode system
Segments: All fields with genetic tests.
Clients: Genetic testing Platforms and genetic tests companies.

CONTACTS:

Contact Name: Ana Teresa Freitas, CEO

Address:
HeartGenetics
Genetics and Biotechnology, S.A.
Biocant Park, Núcleo 4, Lote 4 A
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 896
Email: contact@heartgenetics.com
www.heartgenetics.com

IMMUNETHEP

FOR A SAFE TOMMOROW

DESCRIPTION

Immunethep is a Spin-off from the University of Porto that uses proprietary technology to address unmet medical needs.

The first product in the current technology pipeline is a vaccine to protect neonates from bacterial infections. The proprietary technology used to develop this vaccine is the outcome of more than 30 years of research at the Instituto de Ciências Biomédicas Abel Salazar (ICBAS) of the University of Porto.

Currently there is no available treatment to prevent bacterial infections in fetus and bacterial sepsis in newborns. Immunethep is addressing this unmet medical need in order to prevent the pain and cost of stillbirths, newborn deaths and morbidity due to bacterial infections.

Bacterial sepsis is responsible for the death of 1.35 million Babies, stillbirths and 1-month old, every year. In addition, preterm birth and morbidity caused by bacterial infections represent an annual cost of nearly US$ 12B a year in the US alone.

IMMUNOTHERAPY

Immunethep is a biotechnology company focused on drug development for Immune System related pathologies. Our first product is a vaccine to prevent Sepsis in Neonates.

PRODUCTS & SERVICES

The neonatal vaccine (PNV1), administered to women, induces the production of protective antibodies in the mother that will be transferred to the fetus protecting the fetus and newborn from bacterial infections. Pre-clinical trials in a mice model of infection showed over 80% survival rate in neonates from immunized mothers, contrasting with less than 10% survival in pups born from non-immunized mothers.

PNV1 is currently finishing pre-clinical phase Using the same proprietary technology we are also developing additional undisclosed products addressing unmet medical needs.

TARGET MARKETS / CLIENTS

The neonatal vaccine (PNV1) is destined to women in the fertile age, reaching in 2030 a target population of 2 billion, among whom 300 million reside in the in the world's More Developed Regions.

CONTACTS:

Contact Name: Pedro Madureira

Address:
Immunethep
Biocant Park, Núcleo 4, Lote 3
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 890
Email: info@immunethep.com
www.immunethep.com

DESCRIPTION

iUZ vision is to be recognised as the agile enterprise in delivering unpaired solutions for the future.

Our refreshing engineering approach delivers bespoke and open solutions that empower our customers' business activities.

We focus our work in:

/ Clinical Studies, with an information system to collect and process clinical data
/ Interoperability Platforms, focused on Healthcare
/ Procurement Markets, with flexible business models

At iUZ we aim to make a difference every single day.

HEALTHCARE IT

CLINICAL STUDIES

INTEROPERABILITY

Planning to gather clinical information?
Delivering specialized technology for Clinical Studies, uEDC offers the flexibility to acknowledge your singular scenario, with tools merged into a rich interaction.

PRODUCTS & SERVICES

At iUZ we give our best to fit our clients needs, helping them achieve their goals. We offer ICT Innovation Consultancy and Software Engineering, focused on:

/ Clinical Studies. Our *uEDC – Electronic Data Capture* solution delivers specialised technology for the healthcare field, through an information system to collect and process clinical data, with patients, researchers and professionals. Know more at uedc.iuz.pt

/ Interoperability Platforms. Our *uIN – eHealth Interoperability* solution provides semantic and technical interoperability services and tools to boost the exchange of health-related information among communities. Know more at uin.iuz.pt

/ eMarkets. Our *uBIZ – Procurement Market* solution delivers highly customisable solutions with flexible business models, bringing together offer and demand, solving unwanted time and geographic gaps. Know more at ubiz.iuz.pt

TARGET MARKETS / CLIENTS

At iUZ we shape our tech to answer the constant challenges of the healthcare market. A market that is always evolving where the challenge is to innovate with quality in order to increase efficiency and equalize access.

Keeping the focus on the patient, our solutions allow easier access to healthcare services, continuous patient monitoring and health information sharing between organizations, communities and countries.

Final clients:

/ Research Institutions that organize studies
/ Clinical Research Organisation (CRO)
/ Pharmaceutical Industry
/ National Health Agencies
/ Health Promotion Organizations
/ Healthcare Communities

CONTACTS:

Contact Name: Luís Barata da Rocha

Address:
iUZ Technologies, Lda.
Rua Calouste Gulbenkian, n.º 1
3810-074, Aveiro, PORTUGAL

Phone: (+351) 234 247 381
Email: contact@iuz.pt
www.iuz.pt

Innovative Technologies
from Cloning, S.A.

CLONING THE FUTURE

DESCRIPTION

KLON is a biotechnology company dedicated to research and development of plant tissues, intended for genetic improvement, production and cloning, to achieve desirable agro-forestry features. Our strategy is to provide solutions which lead to improved performance of each specie in terms of adaptability, growth and yield.Regarding our services, we highlight an expert advice on plant cloning using in vitro culture tools, genotyping technologies and cryopreservation of improved plants, strongly directed to the industry, including timber, pulp and paper, resin and energy.

PLANT
BIOTECHNOLOGY

For resin, energy, timber, pulp and paper industries, KLON offers an innovative strategy to enhance plant productivity based on services that combine advanced biotechnology tools for plant breeding assistance with the knowledge of the forestry sector.

PRODUCTS & SERVICES

Klon offers high value products and services to the market and its customers, namely:

/ Tissue culture derived plant clones and seedlings of various species, with superior quality, according to the requirements and needs of the clients;

/ Genetically selected plants for forest deployments with increased productivity and sustainable production;

/ Preservation of selected plant material with important forestry productivity traits through the cryopreservation techniques;

/ Advisory services in plant breeding for agro-forestry industry, developing advanced biotechnologies for plant improvement.

TARGET MARKETS / CLIENTS

/ Forest companies

/ Pine Chemical industries (Resin and its derivatives)

/ Timber industries

/ Pulp and paper

/ Energy crops (Forest biomass)

/ Wine producers

/ Crop producers (eg. Oil)

/ R&D institutes

CONTACTS:

Contact Name: Vanessa Pereira

Address:
Klon, Innovative Technologies from Cloning, S.A.
Biocant Park, Núcleo 04, Lote 4A,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 966
Email: info@klon.pt
www.klon.pt

BUILDING THE FUTURE OF HEALTHCARE

DESCRIPTION

Lymphact is a biopharmaceutical start-up focused on developing innovative personalised medical treatments.

We created a new technology platform which can generate autologous and allogeneic cellular immune therapies for clinical applications – the DOT-Cells®.

BIOPHARMACEUTICAL

CELLULAR
IMMUNOTHERAPY

Lymphact develops innovative personalised medical treatments.
An improved anti-tumour function and the absence of severe associated side-effects are distinctive and unique features of our technology.

PRODUCTS & SERVICES

After 5 years of pioneering research and development, we created a new technology platform which can generate autologous and allogeneic cellular immune therapies for clinical applications – the DOT-Cells®.

DOT-Cells® can target not only cancer and virus infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs, believed to cause disease recurrence. An improved anti-tumour function and the absence of severe associated side effects are distinctive and unique features of our therapeutic approach. Our patents are deployed in the US, EU, Japan and China and our first product will target Leukaemia.

We successfully completed the pre-clinical trials and will enter the clinical stage of the project in the last quarter of 2015.

Of note, Dot-Cells®:
/ can be produced for a much lower cost than our main cell therapy competitors;
/ is simple and optimized for clinical large-scale production;
/ has broad application to several types of cancer diseases.

TARGET MARKETS / CLIENTS

Our first product is an autologous cell therapy, designed to treat patients with chronic lymphocytic leukaemia (CLL). CLL is a disease that affects a specific type of white blood cells, called B lymphocytes. It is the most common leukaemia in adults, representing around 35% of all leukaemia.

The ultimate goal for Lymphact is launching the DOT-Cells® in the market. In order to do so, however, several steps have to be taken. We have already finalised all pre-clinical research for the CLL product, and we are currently composing the regulatory documents necessary for initiating the phase I/IIa Clinical Trial in Europe. Following this major milestone, Lymphact will continue the clinical development of the product, until, finally, submitting a market authorization application.

Concurrently, we shall develop other products, which must follow the same path. Ultimately, we expect to have a wide range of cellular products available for cancer sites with unmet medical needs, including allogeneic cell therapies.

CONTACTS:

Contact Name: Diogo Anjos

Address:
Lymphact - Lymphocyte Activation Technologies, S.A.
Largo dos Colegiais, Nº 2,
7004-516 Évora, PORTUGAL

Email: info@lymphact.com
www.lymphact.com

Luzitin

YOUR WELLNESS MATTERS

DESCRIPTION

Luzitin is a privately owned pharmaceutical company, focused on the development of innovative photosensitizer compounds for Photodynamic Therapy (PDT) or diagnosis (PDx) of cancer and other diseases.

Founded in 2010, Luzitin emerged as a spin-off company from a collaboration beteen Bluepharma, and the University of Coimbra. Its most advanced project (LUZ11) is currently in Phase IIa clinical trials in the treatment of solid tumors.

PHOTODYNAMIC THERAPY (PDT)

ONCOLOGY

IMMUNOGENIC

Innovative therapeutic solutions for cancer therapy.

PRODUCTS & SERVICES

Luzitin is developing a promising therapeutic procedure for solid tumors. The technology consists of a combination of new generation photosensitizer (LUZ11) with a specific infrared-laser medical device. The main benefits are: high efficacy; easy to use; absence of systemic adverse effects; cost-effective.
In vivo studies indicate that, in addition to its strong cytotoxic and vascular effects, this therapeutic approach leads to significant antitumor immune response, thus hampering metastatic processes to occur.
The therapeutic protocol consists of a 30 min procedure and can be conducted at an outpatient basis. No skin phototoxicity is observed both at indoor and at outdoor light.
Due to its benefits and advantages over existing therapeutic approaches, LUZ11 presents unique features to be a first line therapy for solid tumors accessible by light, including pre-cancerous lesions.
LUZ11 already has promising phase II clinical data, clearly reinforcing the favorable PK properties, convenience of use, safety profile and efficacy previously demonstrated in non-clinical studies.
Recently, Luzitin has achieved a very relevant asset, an Orphan Medicinal Product Designation for the treatment of Biliary Tract Cancer, a Life-threatening and chronically debilitating condition.
Submission of EMA Scientific advice and FDA IND application are planned for summer of 2015.

TARGET MARKETS / CLIENTS

Our main compound (LUZ11) aims at the worldwide market.

At this stage Luzitin is looking for partnerships in order to further proceed on the clinical development of our technology, with:

/ Pharmaceutical Industry: Companies with the potential to In-Licensing Luzitin pipeline products.
/ Investment companies: Investors (focus in Venture Capital) willing to proceed the development of LUZ11.

CONTACTS:

Contact Name: Sérgio Simões | Tobias Silva

Address:
Edf. Bluepharma
S. Martinho do Bispo, 3045-016 Coimbra
PORTUGAL

Phone: (+351) 239 800 300
Fax: (+351) 239 800 333
Email: ssimoes@luzitin.pt | tobias.silva@luzitin.pt
www.luzitin.pt

DESCRIPTION

Magnomics is a biotech start-up, spin-off from Portuguese academia, focused on delivering the next generation of fully portable in-vitro molecular diagnostic devices.

Its novel proven technology, currently being prototyped, allows for the detection of bacteria in any substrate without the need for specialized facilities while reducing the lead time for treatments. With broad applications in both human and animal health, Magnomics has chosen bovine mastitis - an ailment affecting dairy cows - as its first market.



MEDICAL
DEVICES

IN-VITRO
DIAGNOSTICS

BACTERIAL
DETECTION

Magnomics delivers the next generation of portable in-vitro molecular diagnostic devices for bacterial detection. We extract DNA, amplify and detect it, all in a small device. It is a lab, on a chip.

PRODUCTS & SERVICES

Our product consists of a portable device with inbuilt sample treatment (swab of fluid), including bacteria separation and DNA purification. After amplification, also performed by the device, the DNA is identified via magnetic detection on the surface of a small chip, which can detect up to thousands of different strands, including antibiotic resistance genes. This chip is part of a disposable, one-off cartridge that is inserted into the reader and that can be produced to meet the diagnosis needs of the client. The readout consists, in the first version, of a simple yes/no marker for each type of bacteria and gene, which can be sent via email or text message to the user.

Magnomics will deliver the frist fully portable, easy to use diagnostic device that provides fast and accurate results in any environment at a competitive cost.

The technology is protected by a growing pool of international patents and is currently being prototyped. A first version of the product is predicted for testing in late 2015.

TARGET MARKETS / CLIENTS

Market applications for this technology are broad and include:

/ Human health: detection and control of hospital infections and multiresistant bacteria

/ Animal health: initial market (see below)

/ Food industry: contamination assessment and general quality control applications

/ Military: applications in biochemical warfare and security checks for bio-agents

Magnomics is currently focused on animal health applications. In particular, we are addressing a key veterinary problem: bovine mastitis, an ailment affecting dairy cows with devastating economical impact worldwide.

At this stage, final clients include both dairy producers and veterinarians. For initial international expansion, we are interested in engaging distributors to sell our product in key EU markets and in the US, as well as in Brazil.

Other applications of this technology, as listed above, will be explored through IP licensing with key technology partners.

CONTACTS:

Contact Name: Filipe Arroyo Cardoso

Address:
Magnomics
Biocant Park, Núcleo 04, Lote 02,
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 938 407 433
Fax: (+351) 231 410 899
Email: info@magnomics.pt
www.magnomics.pt

Reg4life
Regeneration Technology, S.A.

SHAPING THE FUTURE IN BONE REGENERATION

DESCRIPTION

Reg4life is a new SME company focused on R&D innovations on materials and biomedical devices especially for bone regeneration in dentistry, orthopaedics and applications in tissue engineering. The aim is to combine the expertise coming from different complementary areas (materials development and processing, biology and medicine) to develop a new generation of implantable medical devices.



RESEARCH

DEVELOPMENT

COMMERCIALIZATION

Reg4life aims at shaping the future in bone regeneration through a new generation of customized implant devices fabricated from fast healing materials.

PRODUCTS & SERVICES

Reg4life acquired (from University of Aveiro) a recent patent on alkali-free bioactive glasses, which were also registered under the "FastOs®BG" mark. Protecting the IPR is being made at international level.

Trials aiming at validating FastOs®BG materials for bone reconstruction and tissue engineering, following the standard protocols established by international health authorities are underway.

The results are essential for ensuring approval and product certification before its introduction in the market.

The products are scaffolds with controlled porosity to support bone regeneration, including customer made implants fabricated by modern and innovative manufacturing techniques, and bone filling materials (powders, spheres, fibres, cements, etc.) according to the declared or perceived needs from the health professionals.

Reg4life aims to become a reference in searching and providing better health solutions in the demanding area of regenerative medicine.

TARGET MARKETS / CLIENTS

At Reg4life we are specially focused on multifunctional materials and biomedical devices for the regeneration of hard tissues. The main target markets are those related to dentistry and orthopaedics applications, but not excluding other areas such as nerve regeneration and wound healing.

The potential clients include:

/ Hospitals, clinics and other health institutions;

/ Representatives of biomedical materials and devices;

/ Pharmaceutical and biotechnology companies or institutions engaged in experimental, pre-clinical and clinical research in the area of tissue engineering and regenerative medicine.

/ Companies interested in developing specific regenerative biomedical products targeting degenerative bone diseases such osteoporosis, osteomyelitis, malignant tumours, or traumatic accidents (traffic/working/sports).

CONTACTS:

Contact Name: Firmino Rocha

Address:
Reg4life - Regeneration Technology, S.A.
Biocant - Associação de Transferência de Tecnologia
Parque Tecnológico de Cantanhede, Núcleo 04, Lote 3
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 419 040
Email: firmino.rocha@reg4life.com
pedro.mendes@reg4life.com
jose.ferreira@reg4life.com
www.reg4life.com

Stemmatters

THERAPEUTIC DEVELOPMENT
AND MANUFACTURING FOR
REGENERATIVE MEDICINE

DESCRIPTION

Stemmatters is a regenerative medicine company focused on R&D and manufacturing of cell based products.

The company is developing new biomaterials and tissue engineering products for cartilage repair and regeneration, which demonstrate benefit as compared to current standard of care. In addition to its R&D laboratories, the company also has clean rooms for processing tissues and cells and contract manufacturing of cell based products. Stemmatters is QMS compliant with GLP, GMP and ISO 9001:2008 certification.

TISSUE ENGINEERING

CELL BASED PRODUCTS

CONTRACT DEVELOPMENT AND MANUFACTURING

Stemmatters provides innovative solutions for tissue engineering and regenerative medicine and offers a one-stop shop for contract development and manufacturing of cell based products.

PRODUCTS & SERVICES

Stemmatters develops innovative regenerative medicine products that progress standard of care and improve quality of life. Our products under development target:

/ Osteoarthritis: New glycosaminoglycan analogue formulation to be administered by intra-articular injection, exhibiting prolonged degradation time and enhanced bioactive profile, aimed at promoting chondroprotection in diseased joints.

/ Cartilage lesions: Novel tissue engineering product aimed at addressing focal cartilage lesions, which enables single step treatment of patients by a minimally invasive procedure, and speeds up recovery time, while reducing treatment cost in an outpatient setting.

Stemmatters provides contract research and development in medical devices and advanced therapy medicinal products, by encompassing experimental development, in vitro performance assessment and in vivo testing. Stemmatters assures manufacturing of cell based products in compliance with current regulations and cGMP guidelines.

TARGET MARKETS / CLIENTS

Markets:
Regenerative medicine
Tissue Engineering
3D cell culture systems

Clients:
Pharmaceutical and biotechnology companies or institutions engaged in experimental, pre-clinical and clinical research in the area of tissue engineering and regenerative medicine.

Pharmaceutical and biotechnology companies engaged with the development and application of 3D cell culture systems.

Companies interested in developing regenerative medicine products targeting musculoskeletal diseases.

CONTACTS:

Contact Name: Rui Amandi de Sousa

Address:
StemMatters - Biotecnologia e Medicina Regenerativa, S.A.
Parque de Ciência e Tecnologia Avepark,
Zona Industrial da Gandra,
4805-017 Barco GMR, PORTUGAL

Phone: (+351) 253 540 100
Fax: (+351) 253 540 199
Email: rasousa@stemmatters.com
www.stemmatters.com

TOXFINDER PROVIDES IN VITRO TOXICITY TESTS IN ACCORDANCE WITH THE EUROPEAN LEGISLATION

DESCRIPTION

TOXFINDER is strongly committed with the European Cosmetic and REACH regulation by actively seeking for the reduction of animals in toxicological screenings. Our approach is based on the principle that the analysis and integration of multi endpoints in *in vitro* cell models could be employed to create highly predictive models of human toxicity. We help our clients to quickly understand the safety profiles of new products allowing them to move about those with the lowest risk for toxicity and hence the highest probability of regulatory and commercial success to market.



SAFETY
ASSESSMENT

PREDICTIVE
TOXICITY

NON-ANIMAL
TESTS

TOXFINDER provides in vitro toxicity models with real predictive power designed to increase competitiveness in an ever changing regulatory, for cosmetic, toiletry and chemical companies.

PRODUCTS & SERVICES

TOXFINDER deploys already established *in-vitro* toxicological tests such as hepatic toxicity, cutaneous irritation, immunotoxicity, mitochondrial toxicity, phototoxicity and develops new non-animal predictive methodologies to offer to the cosmetic, pharmaceutical and chemistry industries. Our first proprietary product,SENSITIZER PREDICTOR, is an in vitro alternative test that identifies the sensitization potential of chemicals and cosmetic ingredients. Besides the ethical and legal advantages, our technology is more economic and less time consuming than the current animal tests and has been recently submitted to the European Center for Validation of Alternative Methods (ECVAM). TOXFINDER is also optimizing a complementary test that will allow the estimation of the potency of the identified sensitizers. Our product roadmap includes the development of a panel of nanotoxicity tests and the establishment of a model for respiratory toxicity evaluation.

TARGET MARKETS / CLIENTS

TOXFINDER, is focused on the development of non-animal predictive toxicity tests that will help Cosmetic, Toiletry, Chemical and Pharmaceutical Industries to meet the existing and forthcoming legislation. Our final clients are the cosmetic bio/ pharmaceutical, chemical and nutraceutical companies.

CONTACTS:

Contact Name: Bruno Neves

Address:
Toxfinder, Lda.
Instituto Pedro Nunes, Rua Pedro Nunes,
3030-199, Coimbra, PORTUGAL

Phone: (+351) 231 419 040
Fax: (+351) 231 419 049
Email: toxfinder.lda@gmail.com
www.biocant.pt

TREAT U

ADDRESSING THE TUMOR MICROENVIRONMENT WITH TARGETED NANOTECHNOLOGIES

DESCRIPTION

TREAT U is developing more effective and safer products for cancer patients by increasing therapeutic efficacy and reducing adverse side effects, hence reducing treatment costs for healthcare systems.

Our first product - PEGASEMP™ - is a proprietary nanotechnology-based delivery platform with application in diagnostics and therapy. PEGASEMP™ targets specifically the tumor microenvironment with triggered delivery of the payload, creating new opportunities in personalized medicine and new value to the Pharmaceutical Market.



NANOMEDICINE

ONCOLOGY

DRUG DELIVERY

At TREAT U, we develop more effective and safer nanotechnology-based therapies for cancer patients, by targeting the tumor microenvironment with triggered release of the therapeutic agents.

PRODUCTS & SERVICES

PEGASEMP™ is a proprietary nanotechnology-based drug delivery platform with application in diagnostics and therapy. PEGASEMP™ is innovative in the way that it targets specifically the tumor microenvironment with programmed delivery of the payload, upon cellular internalization. The specificity of the platform is based on a ligand-receptor interaction with cancer cells and cells from the tumor blood vessels.

PEGASEMP™ has concluded scale-up and preclinical general toxicity GLP trials, according to a regulatory approved plan. Clinical trials phase I/IIa are scheduled for 2015.

PEGASEMP™ has an established preclinical proof-of-concept with demonstration of specificity to human samples of breast and lung cancer, including triple negative breast cancer and non-small-cell lung cancer. In an animal model of breast cancer, PEGASEMP™ was able to suppress tumor cell invasion to adjacent tissues with no evidence of side effects.

PEGASEMP™ has 3 patents granted in US, and a PCT pending in Europe.

TARGET MARKETS / CLIENTS

TREAT U relates to the targeted cancer therapies segment of the Oncology market.

Oncology sales worldwide are estimated to grow from $64.6bn into $104.1bn during the period of 2011-2018 (growth rate of 7.1% and 11.1% market share) (EvaluatePharma 2012).

Collective sales for the marketed targeted cancer therapies are to increase from $30bn in 2011 to $37.2bn in 2014 in the seven major markets (USA, Japan, France, Germany, Italy, Spain and UK), (growth rate of 7.36%) (Market and Product Forecasts: Targeted Cancer Therapies 2011–21), which represents a promising future for a company like TREAT U.

Our revenue model aims at out-licensing the technology to an international pharmaceutical company with skills and track record in Oncology, interested in conducting the later stage of clinical development and commercializing the product worldwide. This is a model validated and adopted by the majority of Pharmaceutical Industries, interested in renewing their pipeline with low risk of investment.

CONTACTS:

Contact Name: Vera Moura

Address:
TREAT U
Parque Industrial de Taveiro, Lote 44
3045-508 Coimbra, PORTUGAL

Phone: (+351) 230 800 360 / (+351) 939 623 486
Email: vera.moura@treatu.pt
www.treatu.pt

P-BIO
Discovery is in our DNA

Parque Tecnológico de Cantanhede,
Núcleo 04, Lote 3
3060-197 Cantanhede, PORTUGAL

Phone: (+351) 231 410 890
Email: info@pbioportugal.pt



biocant

P-BIO
Portugal's Biotechnology Industry Organization
Associação Portuguesa de BioIndústria

Co-funding:

COMPETE
PROGRAMA OPERACIONAL FACTORES DE COMPETITIVIDADE

QREN QUADRO DE REFERÊNCIA ESTRATÉGICO NACIONAL
PORTUGAL 2007.2013

UNIÃO EUROPEIA
Fundo Europeu de Desenvolvimento Regional